These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1318507)

  • 1. Active specific immunotherapy with vaccinia melanoma oncolysate.
    Wallack MK; Scoggin SD; Sivanandham M
    Mt Sinai J Med; 1992 May; 59(3):227-33. PubMed ID: 1318507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in disease-free survival of melanoma patients in conjunction with serologic response in a phase Ia/Ib Southeastern Cancer Study Group trial of vaccinia melanoma oncolysate.
    Wallack MK; Bash J; Bartolucci A
    Am Surg; 1989 Apr; 55(4):243-7. PubMed ID: 2650593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological evaluation of melanoma patients in a phase I/II trial of vaccinia melanoma oncolysate (VMO) immunotherapy.
    Wallack MK; Bash JA; McNally KR; Leftheriotis E
    Cancer Detect Prev Suppl; 1987; 1():351-9. PubMed ID: 3155379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
    Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
    J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment.
    Wallack MK; Meyer M; Bourgoin A; Doré JF; Leftheriotis E; Carcagne J; Koprowski H
    J Biol Response Mod; 1983; 2(6):586-96. PubMed ID: 6663322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.
    Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty LE; Richards JM; Bartolucci AA
    Cancer; 1995 Jan; 75(1):34-42. PubMed ID: 7804974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO).
    Wallack MK; McNally K; Michaelides M; Bash J; Bartolucci A; Siegler H; Balch C; Wanebo H
    Am Surg; 1986 Mar; 52(3):148-51. PubMed ID: 3513682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.
    Adamina M; Weber WP; Rosenthal R; Schumacher R; Zajac P; Guller U; Frey DM; Oertli D; Zuber M; Heberer M; Spagnoli GC
    Contemp Clin Trials; 2008 Mar; 29(2):165-81. PubMed ID: 17707139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
    Berthier-Vergnes O; Portoukalian J; Lefthériotis E; Doré JF
    Cancer Res; 1994 May; 54(9):2433-9. PubMed ID: 8162593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial.
    Wallack MK; Sivanandham M; Ditaranto K; Shaw P; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Rosen L; Bartolucci AA
    Ann Surg; 1997 Aug; 226(2):198-206. PubMed ID: 9296514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial.
    Wallack MK; Sivanandham M; Whooley B; Ditaranto K; Bartolucci AA
    Ann Surg Oncol; 1996 Mar; 3(2):110-7. PubMed ID: 8646509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview analysis of adjuvant therapies for melanoma--a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials.
    Kim EM; Sivanandham M; Stavropoulos CI; Bartolucci AA; Wallack MK
    Surg Oncol; 2001; 10(1-2):53-9. PubMed ID: 11719029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates.
    Wallack MK; Michaelides M
    Surgery; 1984 Oct; 96(4):791-800. PubMed ID: 6091287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
    Doré JF; Portoukalian J; Berthier-Vergnes O; Jacubovich R; Genève J; Bailly M; Lefthériotis E; Weissbrod A; Mayer M
    Bull Cancer; 1990; 77(9):881-91. PubMed ID: 2224160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
    Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
    Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
    Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
    Rosenthal R; Viehl CT; Guller U; Weber WP; Adamina M; Spagnoli GC; Heberer M; Zuber M
    J Am Coll Surg; 2008 Jul; 207(1):95-105. PubMed ID: 18589368
    [No Abstract]   [Full Text] [Related]  

  • 18. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
    Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
    Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma.
    Elliott GT; McLeod RA; Perez J; Von Eschen KB
    Semin Surg Oncol; 1993; 9(3):264-72. PubMed ID: 8516615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
    MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
    Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.